» Articles » PMID: 35255209

A New Class of Bi- and Trifunctional Sugar Oximes As Antidotes Against Organophosphorus Poisoning

Abstract

Recent events demonstrated that organophosphorus nerve agents are a serious threat for civilian and military populations. The current therapy includes a pyridinium aldoxime reactivator to restore the enzymatic activity of acetylcholinesterase located in the central nervous system and neuro-muscular junctions. One major drawback of these charged acetylcholinesterase reactivators is their poor ability to cross the blood-brain barrier. In this study, we propose to evaluate glucoconjugated oximes devoid of permanent charge as potential central nervous system reactivators. We determined their reactivation efficacy on inhibited human acetylcholinesterase, the crystal structure of two compounds in complex with the enzyme, their protective index on intoxicated mice, and their pharmacokinetics. We then evaluated their endothelial permeability coefficients with a human model. This study shed light on the structural restrains of new sugar oximes designed to reach the central nervous system through the glucose transporter located at the blood-brain barrier.

Citing Articles

Novel uncharged triazole salicylaldoxime derivatives as potential acetylcholinesterase reactivators: comprehensive computational study, synthesis and evaluation.

Baghersad M, Habibi A, Dehdashti Nejad A RSC Adv. 2023; 13(41):28527-28541.

PMID: 37780731 PMC: 10534079. DOI: 10.1039/d3ra05658a.


Strategies for enhanced bioavailability of oxime reactivators in the central nervous system.

Prchalova E, Kohoutova Z, Knittelova K, Malinak D, Musilek K Arch Toxicol. 2023; 97(11):2839-2860.

PMID: 37642747 DOI: 10.1007/s00204-023-03587-0.


Therapy of Organophosphate Poisoning via Intranasal Administration of 2-PAM-Loaded Chitosomes.

Vasilieva E, Kuznetsova D, Valeeva F, Kuznetsov D, Zakharov A, Amerhanova S Pharmaceutics. 2022; 14(12).

PMID: 36559339 PMC: 9781263. DOI: 10.3390/pharmaceutics14122846.


Pioglitazone Attenuates the Effects of Peripheral Inflammation in a Human In Vitro Blood-Brain Barrier Model.

da Rocha G, Loiola R, de Paula-Silva M, Shimizu F, Kanda T, Vieira A Int J Mol Sci. 2022; 23(21).

PMID: 36361571 PMC: 9656730. DOI: 10.3390/ijms232112781.

References
1.
Chai P, Hayes B, Erickson T, Boyer E . Novichok agents: a historical, current, and toxicological perspective. Toxicol Commun. 2018; 2(1):45-48. PMC: 6039123. DOI: 10.1080/24734306.2018.1475151. View

2.
Cornford E, Hyman S . Localization of brain endothelial luminal and abluminal transporters with immunogold electron microscopy. NeuroRx. 2005; 2(1):27-43. PMC: 539318. DOI: 10.1602/neurorx.2.1.27. View

3.
Zorbaz T, Braiki A, Marakovic N, Renou J, De La Mora E, Macek Hrvat N . Potent 3-Hydroxy-2-Pyridine Aldoxime Reactivators of Organophosphate-Inhibited Cholinesterases with Predicted Blood-Brain Barrier Penetration. Chemistry. 2018; 24(38):9675-9691. DOI: 10.1002/chem.201801394. View

4.
Santoni G, de Sousa J, De La Mora E, Dias J, Jean L, Sussman J . Structure-Based Optimization of Nonquaternary Reactivators of Acetylcholinesterase Inhibited by Organophosphorus Nerve Agents. J Med Chem. 2018; 61(17):7630-7639. DOI: 10.1021/acs.jmedchem.8b00592. View

5.
Lorke D, Kalasz H, Petroianu G, Tekes K . Entry of oximes into the brain: a review. Curr Med Chem. 2008; 15(8):743-53. DOI: 10.2174/092986708783955563. View